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ABSTRACT
Background Adenovirus serotype 5 (Ad5) is a commonly 
used viral vector for transient delivery of transgenes, 
primarily for vaccination against pathogen and tumor 
antigens. However, endemic infections with Ad5 produce 
virus- specific neutralizing antibodies (NAbs) that limit 
transgene delivery and constrain target- directed immunity 
following exposure to Ad5- based vaccines. Indeed, clinical 
trials have revealed the limitations that virus- specific NAbs 
impose on the efficacy of Ad5- based vaccines. In that 
context, the emerging focus on immunological approaches 
targeting cancer self- antigens or neoepitopes underscores 
the unmet therapeutic need for more efficacious vaccine 
vectors.
Methods Here, we evaluated the ability of a chimeric 
adenoviral vector (Ad5.F35) derived from the capsid of 
Ad5 and fiber of the rare adenovirus serotype 35 (Ad35) to 
induce immune responses to the tumor- associated antigen 
guanylyl cyclase C (GUCY2C).
Results In the absence of pre- existing immunity to Ad5, 
GUCY2C- specific T- cell responses and antitumor efficacy 
induced by Ad5.F35 were comparable to Ad5 in a mouse 
model of metastatic colorectal cancer. Furthermore, like 
Ad5, Ad5.F35 vector expressing GUCY2C was safe and 
produced no toxicity in tissues with, or without, GUCY2C 
expression. Importantly, this chimeric vector resisted 
neutralization in Ad5- immunized mice and by sera 
collected from patients with colorectal cancer naturally 
exposed to Ad5.
Conclusions These data suggest that Ad5.F35- based 
vaccines targeting GUCY2C, or other tumor or pathogen 
antigens, may produce clinically relevant immune 
responses in more (≥90%) patients compared with Ad5- 
based vaccines (~50%).
INTRODUCTION
Immune checkpoint inhibitor therapies 
have revolutionized cancer treatment and 
cancer drug development by engaging the 
immune system to target various cancers.1 2 
Despite this success, many tumors are immu-
nologically “cold,” characterized by a dearth 
of immunogenic neoepitopes3 and lack of 
tumor- infiltrating lymphocytes,4 5 and remain 
refractory to checkpoint inhibitors.6 7 One 
emerging strategy to modify a cold tumor into 
one responsive to immunotherapy is through 
combination with cancer vaccines.8 9 The 
goal of this strategy is to use cancer vaccines 
to create a pool of tumor- reactive T cells with 
antitumor activity alone and/or in combi-
nation with checkpoint therapies. However, 
this approach is significantly limited by the 
paucity of effective vaccine platforms to safely 
deliver tumor- specific/associated antigens to 
elicit beneficial antitumor immunity.
The ability of adenovirus serotype 5 
(Ad5) to mediate gene transfer and induce 
potent immune responses has made it a 
popular vector for experimental vaccines 
against cancer and infectious diseases.10 
Indeed, there have been more than 400 clin-
ical trials using the Ad5 vector, with most 
trials focused on developing cancer treat-
ments.10 11 However, on natural infection, 
the host immune system develops neutral-
izing antibodies (NAbs) to the Ad5 capsid, 
limiting viral spread and blocking reinfec-
tion. Because Ad5 infections are endemic 
in many human populations, pre- existing 
NAbs present in >70% of the worldwide 
population limit Ad5- based vaccine strate-
gies.12–14 These considerations highlight the 
need for improved vectors for use in vaccines 
targeting cancer and pathogen- associated 
antigens that can create therapeutic immune 
responses in the greatest number of patients. 
Importantly, while the adenovirus capsid 
is composed of hexon, penton, and fiber 
proteins, NAbs elicited by natural Ad5 infec-
tion in humans are directed primarily to the 
Ad5 fiber,15 16 suggesting that strategies to 
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circumvent pre- existing immunity to this element may 
improve Ad5- based vaccines.
Here, we sought to overcome pre- existing Ad5 NAbs by 
replacing the Ad5 fiber with that of a rare adenovirus sero-
type, Ad35 (international seroprevalence ~10%12–14), to 
improve antitumor immunity in mouse models expressing 
the gastrointestinal (GI) cancer antigen guanylyl cyclase 
C (GUCY2C). Preclinical models demonstrated that an 
Ad5- based GUCY2C- directed vaccine (Ad5- GUCY2C- S1) 
elicited CD8+ T- cell and antibody responses without 
autoimmunity.17 18 Further, Ad5- GUCY2C- S1 vaccination 
of mice induced long- term T- cell- mediated protection 
against metastatic colorectal cancer in lung and liver.19 20 
Moreover, those results were recapitulated in a recent 
first- in- human phase I clinical trial (NCT01972737) 
demonstrating that a humanized version of the vaccine 
(Ad5- GUCY2C- PADRE) safely induced GUCY2C- specific 
CD8+ T- cell responses in patients with colorectal cancer 
following conventional therapies.21 However, patients 
possessing high pre- existing titers of NAbs against Ad5 
failed to generate GUCY2C- specific immunity following 
Ad5- GUCY2C- PADRE vaccination.21 To overcome Ad5 
NAbs, we generated a chimeric Ad5 vector possessing the 
fiber of Ad35 (Ad5.F35) with equivalent safety and anti-
tumor activity to Ad5 and resistance to Ad5 NAbs in mice 
and humans. This chimeric vaccine can be translated to 
patients with GI cancer to safely induce GUCY2C- specific 
immunity not only in those patients with low Ad5 immu-
nity but also in those with high pre- existing Ad5 NAbs.
MATERIALS AND METHODS
Adenovirus vectors
Adenovirus containing mouse extracellular domain 
(GUCY2C1-429) with the influenza HA107-119 CD4
+ T- cell 
epitope known as site 1 (S1) was described previously 
(Ad5- GUCY2C- S1).20 Here, GUCY2C- S1 was cloned into 
pShuttle and subcloned into the E1 region of previ-
ously generated replication- deficient chimeric adeno-
virus (Ad5.F35) in which the Ad5 fiber was replaced by 
the Ad35 fiber22 to generate Ad5.F35- GUCY2C- S1. All 
adenovirus vaccines used in this study were produced 
in HEK293 cells and purified by cesium chloride ultra-
centrifugation under Good Laboratory Practices by the 
Baylor College of Medicine in the Cell and Gene Therapy 
Vector Development Lab and certified to be negative for 
replication- competent adenovirus, mycoplasma, and host 
cell DNA contamination. In vitro GUCY2C- expression 
experiments (dose–response and time–course) were 
carried out in A549 (American Type Culture Collection 
(ATCC)) cells. Virus was added to the cultures at the indi-
cated doses and culture supernatants were collected at 
the indicated time points. Relative GUCY2C levels were 
quantified in supernatants by western blot using 2 μg/mL 
MS7 mouse anti- GUCY2C monoclonal antibody23–25 and 
0.1 μg/mL horseradish peroxidase- conjugated goat anti-
mouse secondary antibody (Jackson Immuno).
Mice and immunizations
Eight- week old male and female BALB/cJ mice were 
purchased from the Jackson Laboratory for experiments. 
Animal protocols were approved by the Thomas Jefferson 
University Institutional Animal Care and Use Committee 
(Protocol 02092). For immunizations, mice received 1010 
or 1011 vp of Ad5- GUCY2C- S1, Ad5.F35- GUCY2C- S1, or 
Ad5.F35- GFP (control) administered as two 50 μL intra-
muscular injections, one in each hind limb, using a 
0.5 mL insulin syringe.
Quantifying T-cell responses by ELISpot
ELISpot assays were performed using a mouse inter-
feron-γ (IFN-γ) single color ELISpot kit (Cellular Tech-
nology) according to the manufacturer’s protocol.26 27 
Briefly, 96- well plates were coated with IFN-γ capture anti-
body overnight at 4°C. The next day, plates were washed 
with phosphate- buffered saline (PBS) and splenocytes 
from immunized mice were plated at 500,000 cells/
well with no peptide or 10 μg/mL GUCY2C254-262 peptide 
in 0.1% dimethyl sulfoxide (DMSO) in CTL- TEST 
medium (Cellular Technology) for 24 hours at 37°C. 
For T- cell avidity studies, splenocytes were plated at 
600,000–800,000 cells/well with decreasing concentra-
tions of GUCY2C254-262 peptide (10 μg/mL to 56 pg/mL) 
normalized to 106 cells/well.26 27 After incubation, cells 
were removed, and development reagents were added to 
detect IFN-γ-producing spot- forming cells. The number 
of spot- forming cells per well was determined using the 
SmartCount and Autogate functions of an ImmunoSpot 
S6 Universal Analyzer (Cellular Technology). GUCY2C- 
specific responses were calculated by subtracting mean 
spot counts of 0.1% DMSO wells from peptide- stimulated 
wells.26 27
Tumor studies
GUCY2C- expressing mouse (BALB/c) CT26 colorectal 
cancer cells were used for in vivo tumor studies.17 
Luciferase- expressing cells were generated by transduc-
tion with lentiviral supernatants produced by 293FT cells 
(Invitrogen) with pLenti4- V5- GW- luciferase.28 For tumor 
experiments, BALB/cJ mice were immunized with 1010 
vp of Ad5- GUCY2C- S1, Ad5.F35- GUCY2C- S1, or PBS 
(control) 7 days before delivering 5×105 CT26 cells into 
tail veins. Tumor burden was quantified weekly by subcu-
taneous injection of 3.75 mg of D- luciferin potassium salt 
(Gold Biotechnologies) in PBS followed by an 8 min incu-
bation and imaging with a 10 s exposure using a Caliper 
IVIS Lumina XR imaging station (PerkinElmer). Total 
radiance (photons/second) was measured using Living 
Image In Vivo Imaging Software (PerkinElmer).
Antibody neutralization assay
Serum samples were obtained previously from patients 
before immunization with Ad5- GUCY2C- PADRE 
(NCT01972737) approved by the Thomas Jefferson Univer-
sity Institutional Review Board.21 Neutralizing antibody 
titers against Ad5 and Ad5.F35 vectors were quantified as 
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described.21 Briefly, dilutions of heat- inactivated serum 
samples were added to 96- well tissue culture plates 
containing 105 A549 cells (ATCC) and infected with 108 vp 
of GFP- expressing Ad5 or Ad5.F35 virus (Ad5- CMV- eGFP 
or Ad5.F35- CMV- eGFP, respectively; Baylor Vector Develop-
ment Lab). Following a 41- hour incubation at 37°C, eGFP 
fluorescence (490 nm excitation, 510 nm emission) was 
quantified using a POLARstar Optimate plate reader (BMG 
Labtech). Sample fluorescence was normalized to control 
wells containing cells and virus (0% neutralization) or wells 
containing cells alone (100% neutralization). Titers were 
quantified using non- linear regression as the serum dilu-
tion producing 50% neutralization (Prism v8, GraphPad 
Software).
Ad5 neutralizing immunity studies
To induce anti- Ad5 immunity, mice were exposed 
intranasally to 1010 Ad5- GFP once or twice at a 4- week 
interval. Thirty days after the last exposure, Ad5 NAbs 
were quantified in sera as described above and mice 
were immunized intramuscularly with 1011 vp of Ad5- 
GUCY2C- S1 or Ad5.F35- GUCY2C- S1.
Biodistribution and toxicology study
BALB/cJ mice were immunized intramuscularly with a 
single dose of 1011 vp of Ad5.F35- GUCY2C- S1, three doses 
of 1011 vp of Ad5.F35- GUCY2C- S1 at 28- day intervals, or PBS 
(control). Animals were monitored for adverse events once 
daily with additional evaluations on the day of dosing (5 min, 
1 hour, and 3 hours after dosing). On days 14 and 90, desig-
nated animals were sacrificed and brain, salivary glands, 
stomach, small intestine, colon, heart, lungs, kidneys, liver, 
and injection site were harvested and weighed for histo-
pathological analysis by a blinded pathologist (pathology 
evaluation was performed by IDEXX BioAnalytics) and 
detection of viral DNA by quantitative PCR (qPCR) using 
the previously described assay for the GUCY2C transgene.19 
Also, spleens were collected for histopathological analysis 
and detection of viral DNA as described above, as well as 
quantification of GUCY2C- specific T- cell responses by IFN-γ 
ELISpot as described above.
Statistical analysis
Statistical analyses were conducted using GraphPad Prism 
Software v8. Statistical significance was considered as follows: 
ns=p >0.05, * p <0.05, **p <0.01, ***p <0.001, and ****p 
<0.0001. Cohort sizes were powered based on prior studies 
with β=0.2 and α=0.05. For multiple comparisons of survival 
outcomes, significance thresholds were corrected using 
the Bonferroni method. To identify vaccine- induced T- cell 
responders and non- responders, a previously described21 
modified distribution- free resampling approach was 
employed and positive T- cell responses were defined as 2× 
compared with DMSO and >20- specific spots/106 cells. To 
determine the impact of gender and number of vaccinations 
on responses, log- transformed vaccine response magnitude 
was compared in mice of different genders, cohorts, and 
treatment regimens for up to three- way interactions, with 
stepwise backward variable selection by Akaike information 
criterion using R29 package MASS.30
RESULTS
Ad5-GUCY2C-S1 and Ad5.F35-GUCY2C-S1 vectors
While Ad5 seroprevalence worldwide exceeds 70% 
(>90% in some regions), Ad35 is ~10% and associated 
with lower titers (figure 1A).12 31 Thus, we constructed 
a chimeric adenovirus (Ad5.F35) composed of Ad5 in 
which the fiber was replaced by the Ad35 fiber and eval-
uated its ability to induce GUCY2C- specific immunity 
and resist Ad5- specific immunity in humans and mice. 
Ad5- GUCY2C- S1 is a replication- deficient human Ad5 
expressing the mouse GUCY2C extracellular domain fused 
to the I- Ed- restricted CD4+ epitope known as site 1 at its 
C- terminus.20 To generate Ad5.F35- GUCY2C- S1, the Ad5 
fiber (L5) was replaced with the Ad35 fiber (figure 1B). 
Replication- deficient Ad5- GUCY2C- S1 and Ad5.F35- 
GUCY2C- S1 generated in HEK293 cells produced dose- 
dependent (figure 1C) and time- dependent (figure 1D) 
expression of GUCY2C- S1 protein in A549 human alve-
olar basal epithelial cells in vitro.
Ad5.F35-GUCY2C-S1 induces GUCY2C-specific antitumor 
immunity
Following in vitro validation of GUCY2C expression by 
Ad5.F35- GUCY2C- S1, we confirmed its ability to induce 
GUCY2C- specific immune responses after vaccination 
in vivo. BALB/c mice immunized intramuscularly with 
1010 vp of Ad5.F35- GUCY2C- S1 produced 54% lower 
GUCY2C- specific CD8+ T- cell responses (figure 2A), and 
no GUCY2C- specific antibody responses (figure 2B), 
compared with Ad5- GUCY2C- S1. Importantly, Ad5 and 
Ad5.F35 vaccines produced GUCY2C- specific CD8+ T cells 
of comparable avidity (figure 2C), a critical determinant 
of the antitumor efficacy of GUCY2C- targeted vaccines.26 
In contrast, GUCY2C- specific antibody responses have 
no detectable antitumor activity.20 32 Similarly, Ad5 and 
Ad5.F35 vaccines produced comparable S1- specific CD4+ 
T- cell responses (figure 2D).
Previous studies revealed that Ad5- GUCY2C vaccines 
induced protective antitumor CD8+ T- cell responses in 
murine models of metastatic colorectal cancer.17–20 25 26 
Thus, BALB/c mice were immunized with Ad5 or Ad5.F35 
expressing GUCY2C- S1 and challenged 7 days later with 
CT26 colorectal cancer cells expressing GUCY2C and 
firefly luciferase. This model specifically emulates 
secondary prevention of metastatic disease, the clinical 
setting for which the GUCY2C vaccine is being devel-
oped.21 As previously demonstrated, Ad5 vaccination 
nearly eliminated metastatic tumor burden (figure 3A,B), 
delayed disease progression (figure 3C), and improved 
survival (figure 3D). Similarly, Ad5.F35 also reduced tumor 
burden (figure 3A,B), disease progression (figure 3C), 
and prolonged survival (figure 3D). Importantly, the effi-
cacy of Ad5- based and Ad5.F35- based GUCY2C vaccines in 
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reducing tumor burden, opposing disease progression, and 
promoting survival was identical (figure 3A–D).
Ad5.F35 resists Ad5-directed immunity in mice and humans
NAbs against Ad5 correlated with poor GUCY2C- specific 
immune responses in patients receiving Ad5- GUCY2C- 
PADRE vaccination, and prior exposure of mice to Ad5 
similarly blunted vaccine- induced immunity.21 Ad5.F35- 
based vaccine resistance to pre- existing Ad5 immunity 
was quantified in a model of respiratory pre- exposure to 
Ad5, the natural route of infection in patients,33 followed 
by vaccination and quantification of GUCY2C- specific 
T- cell responses. Control mice (not pre- exposed to Ad5; 
naive) and those that were pre- exposed once (1×) or twice 
(2×) to intranasal Ad5 were vaccinated after 4 weeks with 
intramuscular Ad5 or Ad5.F35 expressing GUCY2C- S1, 
and immune responses were quantified 2 weeks later 
Figure 1 Construction of Ad5.F35- GUCY2C- S1 and antigen expression. (A) Reported international seroprevalence of Ad5 and 
Ad35.12 (B) The L5 gene encoding the fiber protein from Ad5 was replaced with the L5 gene from Ad35, producing the chimeric 
adenoviral vector Ad5.F35. Recombinant Ad5.F35- GUCY2C- S1 was produced by inserting mouse GUCY2C- S1 into the E1 
region of E1/E3 deleted Ad5.F35. (C and D) The human alveolar basal epithelial cell line, A549, was transduced in duplicate 
with Ad5.F35- GUCY2C- S1 at a multiplicity of infection (MOI) from 0 to 10,000 for 48 hours (C) or at an MOI of 10,000 for 0, 
24, 48, and 72 hours (D). Supernatants from infected cells were analyzed for GUCY2C- S1 protein expression by immunoblot. 
Protein expression was quantified by densitometry and plotted relative to uninfected cells. Error bars indicate mean±SEM. Ad5, 
adenovirus serotype 5.
Figure 2 Immunogenicity of Ad5- GUCY2C- S1 and Ad5.F35- GUCY2C- S1. (A–D) BALB/c mice (n=4–7 mice/group) were 
immunized intramuscularly with control or 1010 vp of Ad5- GUCY2C- S1 or Ad5.F35- GUCY2C- S1 and serum and splenocytes 
were collected 14 days later. GUCY2C- specific CD8+ T- cell responses were quantified by interferon gamma (IFN-γ) ELISpot (A) 
and antibodies were quantified by ELISA (B). (C) GUCY2C- specific T- cell avidity measurements were analyzed by ELISpot using 
non- linear regression (log(agonist) versus normalized response) with comparisons made using the extra sum- of- squares F test. 
Avidity plots depict the regression line (solid) with 95% CIs (dashed). (D) S1- specific CD4+ T- cell responses were measured by 
IFN-γ ELISpot. T- cell responses in (A) and (D) were analyzed by one- way analysis of variance. Values in (A), (B), and (D) indicate 
individual animals, and bars in (A) and (D) indicate means. TCR, T- cell receptor; Ad5, adenovirus serotype 5.
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(figure 4A). As expected, one Ad5 pre- exposure induced 
moderate (<1:200) Ad5 NAbs (online supplementary 
figure S1) and reduced GUCY2C- specific T- cell responses 
~75%, while two pre- exposures induced high (>1:200) 
Ad5 NAbs (online supplementary figure S1) and reduced 
GUCY2C- specific T- cell responses >90% following Ad5 
vaccination (figure 4B). In contrast, GUCY2C- specific 
T- cell responses were reduced only 60% (1× pre- 
exposure) and 80% (2× pre- exposure) following Ad5.F35 
vaccination (figure 4B). Importantly, Ad5.F35 produced 
T- cell responses in a substantially greater fraction of the 
population (80% cohort responses), compared with Ad5 
(30% cohort responses), following serial pre- exposures to 
Ad5 (figure 4C).
These observations in mice were recapitulated using sera 
from patients with colorectal cancer in the Ad5- GUCY2C- 
PADRE phase I trial (NCT01972737).21 Here, NAb titers 
against Ad5 and Ad5.F35 were quantified using an estab-
lished Ad5/Ad5.F35 reporter virus inhibition bioassay in 
serum samples collected prior to vaccination with Ad5- 
GUCY2C- PADRE.21 In these patients, Ad5.F35- specific 
NAb titers were substantially lower than Ad5- specific titers 
(figure 4D). Most importantly, 50% of patients possessed 
low (<1:200) Ad5 NAbs titers (figure 4D,E) which closely 
correlated with a 40% GUCY2C- specific response rate.21 
In striking contrast, 90% had low Ad5.F35 NAb titers, 
suggesting that the vast majority of patients immunized 
with Ad5.F35- based vaccines could produce GUCY2C- 
specific responses (figure 4E). Collectively, these obser-
vations suggest that pre- existing viral immunity induced 
by repeated environmental exposures which neutralizes 
Ad5 delivery platforms may be overcome by the chimeric 
Ad5.F35 vector to enhance fractional population vaccine 
responses.
Safety, biodistribution, and toxicity of Ad5.F35-GUCY2C-S1
Food and Drug Administration IND (Investigational New 
Drug)- enabling studies quantified the toxicity, biodistri-
bution, and immunogenicity of Ad5.F35- GUCY2C- S1 in 
BALB/c mice, employing three schemes to examine acute 
and chronic effects (figure 5A). Cohorts, balanced for 
sex, received 1011 Ad5.F35- GUCY2C- S1 either as a single 
intramuscular injection or as three intramuscular injec-
tions spaced 4 weeks apart, monitored daily, and sacri-
ficed on day 14 or 90 for analysis, as indicated (figure 5A). 
There were no signs of acute or chronic toxicity in the 
in- life phase by observation, weight changes, or survival 
(figure 5B–D). Similarly, there were no clinically signifi-
cant differences in organ weights (online supplementary 
figure S2) or histopathology (not shown) at necropsy. 
Small statistical differences in organ weights were consid-
ered clinically insignificant and were unrelated to vaccine 
exposure (dose, time) (online supplementary figure S2). 
Biodistribution, quantified by qPCR, detected Ad5.F35- 
GUCY2C- S1 at the injection site and in the spleen, but 
not appreciably in other organs, after acute and chronic 
exposures (online supplementary figure S3). Moreover, 
robust CD8+ T- cell responses were quantified at day 14 
that persisted through day 90 in 70% of mice after a 
single administration (figure 5E–G). As expected, CD8+ 
T- cell responses were greater, and persisted in more mice 
(100%), at 90 days after three vaccinations (figure 5E–G).
DISCUSSION
Through decades of gene therapy trials, Ad5 has 
remained a popular vector, while high Ad5 seropreva-
lence remains a barrier to universal vaccination.33 Natural 
respiratory infection can generate long- lived antibodies 
that neutralize Ad5- based vaccines, eliminating transgene 
delivery and potential therapeutic benefit. In that context, 
Ad5 seroprevalence is >70% across multiple countries,12 
highlighting an unmet need for alternative vectors. Here, 
we demonstrate that the chimeric Ad5.F35 resists pre- 
existing Ad5 immunity and induces transgene- specific 
antitumor immunity. Indeed, Ad5.F35 is less susceptible 
to neutralization associated with Ad5 exposure in mice 
and humans and generates a substantially higher propor-
tion of vaccine responders in mice pre- exposed to Ad5. 
These observations support the suggestion that Ad5.F35 
Figure 3 Antitumor efficacy of Ad5- GUCY2C- S1 and Ad5.F35- GUCY2C- S1. (A–D) BALB/c mice (n=10 mice/group) were 
immunized intramuscularly with control or 1010 vp of Ad5- GUCY2C- S1 or Ad5.F35- GUCY2C- S1 and challenged 7 days later 
with a mouse colorectal cancer cell line, CT26, expressing GUCY2C and luciferase. On days 7 and 14 following challenge, mice 
were injected with D- luciferin and imaged (A) to quantify tumor burden (day 14; B). Mice were weighed twice weekly (C) and 
monitored for survival (D). Tumor burden (B) was analyzed by one- way analysis of variance and survival comparisons (D) were 
analyzed by the Mantel- Cox log- rank test. In (B) and (D), asterisks (*) indicate comparisons of GUCY2C vaccines to the control 
and brackets (]) indicate comparisons between Ad5 and Ad5.F35 vaccines. ns, not significant; Ad5, adenovirus serotype 5.
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will produce a higher proportion of vaccine responders 
in patient populations.
The extent to which NAbs to the Ad5 fiber limit rein-
fection is controversial. In some studies, replacing the 
Ad5 fiber with that of another serotype circumvents 
pre- existing Ad5 immunity.34 In contrast, other studies 
suggest that these chimeric adenoviruses do not evade 
pre- existing Ad5 NAbs, suggesting the hexon as the 
major target of antibody neutralization.35 36 In contrast 
to those previous studies, which generated pre- existing 
Ad5 immunity by intramuscular35 or intravenous 
administration,36 here Ad5 immunity was induced by 
intranasal exposure in mice, recapitulating natural 
human respiratory infection.33 Moreover, natural 
pre- existing Ad5 NAbs in patients with colorectal 
cancer, uniformly produced by repeated respiratory 
infections,33 similarly were overcome by the Ad5.F35 
vector. Importantly, the quality of antibody responses 
following adenovirus infection is dependent on the 
route of exposure. Indeed, respiratory infections 
elicit fiber- specific NAbs while intramuscular expo-
sure induce capsid- specific NAbs.15 These qualita-
tive differences in NAb responses, reflecting varying 
routes of immunization, may contribute to observa-
tional discrepancies between laboratories. The present 
studies, using relevant animal models, confirmed and 
validated with patient samples, support the suggestion 
that Ad5.F35- based vaccines should produce clinically 
relevant immune responses in a substantial (~90%) 
proportion of patients.
Figure 4 Ad5.F35 resists neutralization associated with pre- existing anti- Ad5 immunity in mice and humans. (A–C) To 
generate pre- existing immunity to Ad5, BALB/c mice (n=10 mice/group) were exposed intranasally once or twice to 1010 vp 
of Ad5- GFP at 4- week intervals. Four weeks after the final Ad5- GFP exposure, Ad5- exposed and naive mice were immunized 
intramuscularly with 1011 vp of Ad5- GUCY2C- S1 or Ad5.F35- GUCY2C- S1. (B), Two weeks after immunization, GUCY2C- 
specific CD8+ T- cell responses in each group were quantified by interferon gamma (IFN-γ) ELISpot and calculated as the 
% of mean responses in naive mice. Values indicate individual animals and bars indicate means. Ad5 and Ad5.F35 were 
compared by two- way analysis of variance. (C) The fraction of animals producing a detectable GUCY2C- specific CD8+ T- cell 
response (filled regions) in naive, 1×, and 2× Ad5- exposed mice was determined from (B). (D and E) Sera from 10 patients with 
colorectal cancer collected prior to Ad5.GUCY2C- PADRE vaccination were tested for the ability to neutralize Ad5 and Ad5.F35 
vectors and titers were quantified (D; analyzed by paired t- test). The dotted line indicates a titer of 200, the threshold for high 
neutralizing antibody (NAb) titers.21 (E) While 5/10 subjects had high NAb titers (>200) against Ad5, only 1/10 had high titers to 
Ad5.F35 vector (filled regions; binomial test). Ad5, adenovirus serotype 5.
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Recognizing the pervasive limitations imposed by 
endemic Ad5 immunity in global populations,12 there is 
an emerging interest in alternative serotypes and chimeric 
constructs as a tractable strategy in vaccine development. 
Ad26, Ad35, and Ad48 vectors have been advanced 
into phase I clinical trials.37 38 In that regard, a compar-
ison of Ad5, Ad26, Ad35, and Ad48 immunity among 
healthy patients revealed that endemic Ad35 seroposi-
tivity was lowest across global populations,12 reinforcing 
chimeric strategies employed herein. Similarly, the first 
hexon- chimeric adenovirus, comprising Ad5 and Ad48 
components, was safe and immunogenic in patients.39 
Interestingly, Ad5- Ad35 chimeric vectors more efficiently 
transduce a variety of human cell types in vitro compared 
with either parental vector.40 These observations under-
score the future potential of intelligently designed 
chimeric adenoviruses strategically constructed to deliver 
transgenes for replacement therapy or vaccination and 
targeted precisely to the cellular or disease context.40
While antitumor efficacy was equivalent, CD8+ 
T- cell responses were lower, and antibody responses 
were absent, for Ad5.F35- GUCY2C- S1, compared with 
Ad5- GUCY2C- S1. However, the antitumor efficacy of 
GUCY2C- directed immunotherapy is driven primarily by 
T- cell avidity, rather than effector T- cell quantity.26 In that 
context, the functional avidity of GUCY2C- specific CD8+ 
T cells following Ad5 and Ad5.F35 immunizations were 
equivalent, consistent with their comparable antitumor 
efficacy. Quantitative differences in transgene- specific 
immunity between vectors may reflect a variety of factors. 
Thus, the quantity and persistence of GUCY2C- S1 trans-
gene following Ad5.F35 immunization is lower compared 
with Ad5,19 consistent with prior observations that Ad5 
transduction efficiency in vivo may be several- fold higher 
than Ad5.F35.41 Moreover, the Ad5 fiber binds to CXADR 
(coxsackievirus and adenovirus receptor)42 while the 
Ad35 fiber binds to CD46,43 suggesting the two viruses 
may infect distinct cell types.
Figure 5 Safety and immunogenicity of multiple Ad5.F35- GUCY2C- S1 administrations. (A–G) BALB/c mice (n=10 mice/
group) were immunized intramuscularly with one or three administrations of 1011 vp Ad5.F35- GUCY2C- S1 or control at 4- week 
intervals. Following immunization, body weights ((B), female and (C) male)) were recorded weekly and mice were monitored for 
survival (D). At days 14 and 90 following first immunization, mice were euthanized to quantify organ pathology by weight (online 
supplementary figure S2), biodistribution by quantitative PCR (online supplementary figure S3), and GUCY2C- specific CD8+ 
T- cell responses by interferon gamma (IFN-γ) ELISpot (E–G). (G) Pie charts indicate proportion of responding animals. Ad5, 
adenovirus serotype 5.
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While checkpoint inhibitors have generated practice- 
shifting results in the clinic and defined immunotherapy 
as an effective strategy for the treatment of several malig-
nancies, they have not been universally successful. In 
that context, the dearth of neoepitopes in many cancer 
types, including microsatellite stable colorectal and 
pancreatic (second and third leading causes of cancer 
mortality, respectively), makes them insensitive to check-
point blockade.7 Indeed, examination of neoepitopes 
presented on the surface of five colorectal cancer spec-
imens revealed a total of three neoepitopes.3 Thus, 
vaccines targeting cancer- associated self- antigens have 
re- emerged, alone and in combination with checkpoint 
inhibitors, as a strategy to prevent and treat metastases 
from these cold tumors.44 45
Checkpoint inhibitors have become first- line therapy in 
the metastatic setting for some cancers,46 while chimeric 
antigen receptor expressing T cells (CAR- T cells) are 
being deployed in patients with metastatic and refractory 
disease.47 48 In contrast, few cancer immunotherapies 
have been developed for early- stage cancer patients with 
“no evidence of disease” (NED) following conventional 
surgical/radio/chemotherapies, who are at significant 
risk of disease recurrence. Indeed,~25% of stage II, and 
~50% of stage III, patients with colorectal cancer recur 
following surgery and chemotherapy,49 while 70% of 
patients with resectable pancreatic cancer experience 
recurrence.50 Vaccines targeting tumor- associated anti-
gens, such as Ad5.F35- GUCY2C- PADRE, may provide safe 
and effective immunotherapies for the secondary preven-
tion of metastatic disease in patients with NED who are 
otherwise ineligible to receive checkpoint inhibitors or 
CAR- T cells.
The present studies suggest that the chimeric adeno-
viral vector Ad5.F35 may be preferable to the widely 
used Ad5 vector and warrants further investigation. 
Indeed, they suggest that ongoing clinical investiga-
tions of GUCY2C- directed immunotherapy in patients 
with GUCY2C- expressing cancers, including colorectal, 
pancreatic, gastric, and esophageal, could benefit from 
using the Ad5.F35, rather than the Ad5, vector. In that 
context, an upcoming clinical trial will examine the safety, 
immunogenicity, and resistance to pre- existing immunity 
of Ad5.F35- GUCY2C- PADRE in patients with GI cancer 
(NCT04111172). Safe generation of GUCY2C- targeted 
immunity in a high proportion of patients will lead to 
efficacy trials to establish the ability of Ad5.F35- GUCY2C- 
PADRE to prevent recurrence following standard therapy 
in patients with GI cancer, who represent 25% of all 
cancer deaths51 and for whom established immunother-
apies are ineffective.
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